Ipilimumab, a monoclonal antibody directed against CTLA-4, a negative regulator of early phases of T lymphocyte activation in lymph nodes, was approved by the FDA in 2011 for the treatment of patients with advanced melanoma [31]. The gene discussed is CTLA4; the disease is melanoma.